Your browser doesn't support javascript.
loading
Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease.
Blokker, Britt A; Maijo, Monica; Echeandia, Marta; Galduroz, Mikel; Patterson, Angela M; Ten, Anna; Philo, Mark; Schungel, Rebecca; Gutierrez-de Juan, Virginia; Halilbasic, Emina; Fuchs, Claudia; Le Gall, Gwenaelle; Milkiewicz, Malgorzata; Milkiewicz, Piotr; Banales, Jesus M; Rushbrook, Simon M; Mato, José M; Trauner, Michael; Müller, Michael; Martínez-Chantar, María Luz; Varela-Rey, Marta; Beraza, Naiara.
Afiliação
  • Blokker BA; Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
  • Maijo M; Gut Microbes and Health Institute Strategic Programme, Quadram Institute, Norwich, United Kingdom.
  • Echeandia M; Gut Microbes and Health Institute Strategic Programme, Quadram Institute, Norwich, United Kingdom.
  • Galduroz M; Gut Microbes and Health Institute Strategic Programme, Quadram Institute, Norwich, United Kingdom.
  • Patterson AM; Gut Microbes and Health Institute Strategic Programme, Quadram Institute, Norwich, United Kingdom.
  • Ten A; Gut Microbes and Health Institute Strategic Programme, Quadram Institute, Norwich, United Kingdom.
  • Philo M; Gut Microbes and Health Institute Strategic Programme, Quadram Institute, Norwich, United Kingdom.
  • Schungel R; Metabolomics Unit, Quadram Institute, Norwich, United Kingdom.
  • Gutierrez-de Juan V; Gut Microbes and Health Institute Strategic Programme, Quadram Institute, Norwich, United Kingdom.
  • Halilbasic E; Department of Food, Nutrition, Facilities, University of Applied Sciences Münster, Münster, Germany.
  • Fuchs C; CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Spain.
  • Le Gall G; Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria.
  • Milkiewicz M; Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria.
  • Milkiewicz P; Metabolomics Unit, Quadram Institute, Norwich, United Kingdom.
  • Banales JM; Department of Medical Biology, Pomeranian Medical University, Szczecin, Poland.
  • Rushbrook SM; Liver and Internal Medicine Unit, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
  • Mato JM; Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), CIBERehd, Ikerbasque, Donostia, Spain.
  • Trauner M; Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, United Kingdom.
  • Müller M; CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Spain.
  • Martínez-Chantar ML; Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria.
  • Varela-Rey M; Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
  • Beraza N; CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Spain.
Hepatology ; 69(2): 699-716, 2019 02.
Article em En | MEDLINE | ID: mdl-30229970
Cholestasis comprises aetiologically heterogeneous conditions characterized by accumulation of bile acids in the liver that actively contribute to liver damage. Sirtuin 1 (SIRT1) regulates liver regeneration and bile acid metabolism by modulating farnesoid X receptor (FXR); we here investigate its role in cholestatic liver disease. We determined SIRT1 expression in livers from patients with cholestatic disease, in two experimental models of cholestasis, as well as in human and murine liver cells in response to bile acid loading. SIRT1-overexpressing (SIRToe ) and hepatocyte-specific SIRT1-KO (knockout) mice (SIRThep-/- ) were subjected to bile duct ligation (BDL) and were fed with a 0.1% DDC (3,5-diethoxycarbonyl-1,4-dihydrocollidine) diet to determine the biological relevance of SIRT1 during cholestasis. The effect of NorUDCA (24-norursodeoxycholic acid) was tested in BDL/SIRToe mice. We found that SIRT1 was highly expressed in livers from cholestatic patients, mice after BDL, and Mdr2 knockout mice (Mdr2-/- ) animals. The detrimental effects of SIRT1 during cholestasis were validated in vivo and in vitro. SIRToe mice showed exacerbated parenchymal injury whereas SIRThep-/- mice evidenced a moderate improvement after BDL and 0.1% DDC feeding. Likewise, hepatocytes isolated from SIRToe mice showed increased apoptosis in response to bile acids, whereas a significant reduction was observed in SIRThep-/- hepatocytes. Importantly, the decrease, but not complete inhibition, of SIRT1 exerted by norUDCA treatment correlated with pronounced improvement in liver parenchyma in BDL/SIRToe mice. Interestingly, both SIRT1 overexpression and hepatocyte-specific SIRT1 depletion correlated with inhibition of FXR, whereas modulation of SIRT1 by NorUDCA associated with restored FXR signaling. Conclusion: SIRT1 expression is increased during human and murine cholestasis. Fine-tuning expression of SIRT1 is essential to protect the liver from cholestatic liver damage.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colestase / Sirtuína 1 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colestase / Sirtuína 1 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article